Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections
1 other identifier
observational
10
1 country
1
Brief Summary
For patients having a bone or joint infections, with or without device, optimal surgical therapy could be sometimes non-feasible, especially in the elderly population. Therefore, a medical therapy with oral prolonged suppressive antibiotic therapy (PSAT) seems to be an option to prevent recurrence and prosthesis loosening. Subcutaneous (SC) administration of injectable intravenous antibiotics as prolonged suppressive antibiotic therapy could be a convenient way when oral treatment is not available to facilitate ambulatory care, this practice being considered as routine care. The aim of this study is to evaluate tolerance and efficacy of subcutaneous administration of antibiotics for prolonged suppressive antibiotic therapy in patients having this treatment as part of their routine care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2017
CompletedFirst Submitted
Initial submission to the registry
November 20, 2017
CompletedFirst Posted
Study publicly available on registry
January 18, 2018
CompletedJanuary 18, 2018
November 1, 2017
2 months
November 20, 2017
January 10, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Description of sub-cutaneous administration of antibiotics for PSAT
In case of PSAT (prolonged suppressive antibiotic therapy), the duration could be several years. The data collected are: name of molecule, rough, posology, duration.
60 months
Secondary Outcomes (2)
Tolerance of sub-cutaneous administration of antibiotics for PSAT
60 months
Efficacy of sub-cutaneous administration of antibiotics for PSAT
60 months
Eligibility Criteria
Patients having bone or joint infection, with or without device
You may qualify if:
- patients having bone or joint infection,
- patients with or without device treated by sub-cutaneous prolonged antibiotic therapy
You may not qualify if:
- diabetic foot osteomyelitis
- pressure ulcer-associated osteomyelitis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre de Référence des Infections Ostéo-Articulaires complexes (CRIOAc Lyon)
Lyon, 69004, France
Related Publications (1)
Pouderoux C, Becker A, Goutelle S, Lustig S, Triffault-Fillit C, Daoud F, Fessy MH, Cohen S, Laurent F, Chidiac C, Valour F, Ferry T; Lyon Bone and Joint Infection Study Group. Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients. J Antimicrob Chemother. 2019 Jul 1;74(7):2060-2064. doi: 10.1093/jac/dkz104.
PMID: 31220276DERIVED
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 20, 2017
First Posted
January 18, 2018
Study Start
March 1, 2017
Primary Completion
May 1, 2017
Study Completion
August 1, 2017
Last Updated
January 18, 2018
Record last verified: 2017-11
Data Sharing
- IPD Sharing
- Will not share